Abstract:Out of an estimated 31,100 cases since their discovery in 1976, ebolaviruses have caused approximately 13,000 deaths. The vast majority (∼11,000) of these occurred during the 2013-2016 West African epidemic. Three out of five species in the genus are known to cause Ebola Virus Disease in humans. Several monoclonal antibodies against the ebolavirus glycoprotein are currently in development as therapeutics. However, there is still a paucity of monoclonal antibodies that can cross-react between the glycoproteins of different ebolavirus species, and the mechanism of these monoclonal antibody therapeutics is still not understood in detail. Here, we generated a panel of eight murine monoclonal antibodies (MAbs) utilizing a prime-boost vaccination regimen with a Zaire ebolavirus glycoprotein expression plasmid followed by infection with a vesicular stomatitis virus expressing the Zaire ebolavirus glycoprotein. We tested the binding breadth of the resulting monoclonal antibodies using a set of recombinant surface glycoproteins from Reston, Taï Forest, Bundibugyo, Zaire, Sudan, and Marburg viruses and found two antibodies that showed pan-ebolavirus binding. An in vivo Stat2-/- mouse model was utilized to test the ability of these MAbs to protect from infection with a vesicular stomatitis virus expressing the Zaire ebolavirus glycoprotein. Several of our antibodies, including the broadly binding ones, protected mice from mortality despite lacking neutralization capability in vitro, suggesting their protection may be mediated by Fc-FcR interactions. Indeed, three antibodies displayed cellular phagocytosis and/or antibody-dependent cell-mediated cytotoxicity in vitro Our antibodies, specifically the two identified cross-reactive monoclonal antibodies (KL-2E5 and KL-2H7), might add to the understanding of anti-ebolavirus humoral immunity.IMPORTANCE This study describes the generation of a panel of novel anti-ebolavirus glycoprotein monoclonal antibodies, including two antibodies with broad cross-reactivity to all known ebolavirus species. The antibodies were raised using a heterologous DNA-viral vector prime-boost regimen, resulting in a high proportion of cross-reactive antibodies (25%). Similar vaccination regimens have been used successfully to induce broad protection against influenza viruses in humans, and our limited data indicate that this might be a useful strategy for filovirus vaccines as well. Several of our antibodies showed protective efficacy when tested in a novel murine challenge model and may be developed into future therapeutics.

Dual monoclonal antibody-based sandwich ELISA for detection of in vitro packaged Ebola virus

Potent Neutralizing Monoclonal Antibodies Against Ebola Virus Infection

Detection of Ebola Virus Envelope Using Monoclonal and Polyclonal Antibodies in ELISA, Surface Plasmon Resonance and a Quartz Crystal Microbalance Immunosensor.

Structural and Molecular Basis for Ebola Virus Neutralization by Protective Human Antibodies

Development and Characterization of Neutralizing Antibodies Against Zaire Ebolavirus Glycoprotein and Protein 40

Development of an antibody capture ELISA using inactivated Ebola Zaire Makona virus

The Induction and Characterization of Monoclonal Antibodies Specific to GP of Ebola Virus.

Identification and Characterization of a Novel Single Domain Antibody Against Ebola Virus

Production and Characterization of Monoclonal Antibodies Against Gp Protein of Ebola Virus

Dual-Signal Readout Nanospheres for Rapid Point-of-Care Detection of Ebola Virus Glycoprotein

Novel Cross-Reactive Monoclonal Antibodies against Ebolavirus Glycoproteins Show Protection in a Murine Challenge Model

Development of an Immunochromatography Assay (QuickNavi-Ebola) to Detect Multiple Species of Ebolaviruses

Molecular Characterization of the Monoclonal Antibodies Composing ZMAb: A Protective Cocktail Against Ebola Virus

Ebolavirus diagnosis made simple, comparable and faster than molecular detection methods: preparing for the future

Multiplexed Efficient On-Chip Sample Preparation and Sensitive Amplification-Free Detection of Ebola Virus.

Ultrasensitive Ebola Virus Detection Based on Electroluminescent Nanospheres and Immunomagnetic Separation

Visual Detection of Ebola Virus Using Reverse Transcription Loop-Mediated Isothermal Amplification Combined with Nucleic Acid Strip Detection

Generating Uniformly Cross-Reactive Ebolavirus spp. Anti-nucleoprotein Nanobodies to Facilitate Forward Capable Detection Strategies

Ultrasensitive Ebola Virus Antigen Sensing via 3D Nanoantenna Arrays

Cellular-Beacon-Mediated Counting for the Ultrasensitive Detection of Ebola Virus on an Integrated Micromagnetic Platform

Fully human monoclonal antibodies against Ebola virus possess complete protection in a hamster model